RE:RE:RE:RE:RE:SIX POINT DROP/ PRESENTATION YESTERDAY????Hey narmac...I do understand what you are saying, I think.
What I am saying is that ever since June of 2013 there has been a clear and very positive progression from the analysis of the post hoc findings indicating 55% MACE reduction and 77% MACE reduction in patients with DM, CVD and low HDL. The analytical approaches have revealed that apabetalone (rvx-208) acts in a multi-modal manner impacting important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL). In addition to preclinical studies in vitro and in vivo, RVX-208 has been tested in many human trials lasting up to 6 months that in total enrolled almost 1000 patients.
We know that tested out to 6 months that rvx-208 has a positive safety profile. At this stage we don't know beyond that.
I've been extremely critical of RVX regarding poor communications and brand positioning. However, ever since the post hoc findings were released they have been far more active at conferences on both the science and investments sides.
We also need to keep in mind their significant patents, particularly the apabetalone x rosuvastatin (Crestor) combined patent.
I believe there is growing recognition in the scientific and pharma communities about the power of epigenetic approaches to disease management of many different types including CVD, various cancers and diseases caused by inflammation.
So going back to June 2013 we saw the following announcement;
- Resverlogix Corp. (TSX:RVX) today announced that its Phase 2b ASSURE clinical trial evaluating RVX-208 in high-risk cardiovascular patients with low high-density lipoprotein (HDL) did not meet its primary endpoint of a -0.6% change in percent atheroma volume as determined by intravascular ultrasound (IVUS). The RVX-208 treated group had -0.4% plaque regression (p= 0.08). RVX-208 is Resverlogix's first-in-class orally active BET-protein inhibitor.
So it was obvious that market viewed this as a failure. But that is the market. RVX could have thrown in the towel at this stage. However, from a science POV rvx-208 did achieve -0.4% plaque regression with a p=.08, which means that that regression had about a 1 in 12 chance of being a random event. We all know the accepted standard is p=.05 (1 in 20) but that is arbitrary. Scientists realize with 1 in 12 and actual regression there might just be gold in this compound and that it needed to be understood better. Hence the post hocs.
Also keep in mind that the trial design was underpowered. A longer trial could have generated a significant p<.05 as could have a larger sample.
We now have large pieces of that understanding and we understand that apabetalone (rvx-208) has a much broader MOA than initially understood and may be applicable to many other indications.
When we add in the extremely high quality of the BETonMACE steering committee and the scientific talent brought to this drug I believe the interest will grow.
Posts by BDAZ and Bengtpress bring independent scientific perspective to the multi-modal MOA of apabetalone.
With the hiring of Mr. Paradis I feel this is a signal that Don now realizes it is time to get "the good news out".
So that is what I meant by momentum growing. The stock price is extremely low given phase lll BoM. I believe there are a number of reasons and given that my expertise is research and branding I do belive it is time to position this brand and explain it's value to investors including those that want in for the ride up but also for long terms holders. I hold many Zenith shares and hope to benefit from the RVX royalties flowing into Zenith Capital.
I think we all know that this market is huge and growing. Diabetes mellitus is 422,000,000 world wide and with the high carb and sugar diets increasing apabetalone is a gold mine because the cost of diabetes is so costly.
Anyway, a long, and unintended rant but it helped me clear my head. I still believe that we need a NASDAQ listing but this seems beyond Don's capabilities. Perhaps Paradis can help here.
GLTA
Toinv